| Tandem Auto-Allo Transplant for Lymphoma (NCT01181271) | Massachusetts General Hospital | 2010-08-01 |
| A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (NCT01184885) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2010-07-01 |
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma (NCT01148108) | Telik | 2010-06-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) (NCT01170052) | Charite University, Berlin, Germany | 2010-05-01 |
| Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma (NCT01460602) | Louisiana State University Health Sciences Center Shreveport | 2010-05-01 |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients (NCT02354313) | Fondazione Italiana Linfomi - ETS | 2010-05-01 |
| A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (NCT01021423) | Celgene | 2010-04-01 |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT01088048) | Gilead Sciences | 2010-03-25 |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (NCT01078142) | Georg Hess, MD | 2010-02-02 |
| Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) (NCT01073163) | Cephalon | 2010-02-01 |
| A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma (NCT00843050) | Piramal Enterprises Limited | 2009-11-01 |
| Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (NCT00963534) | Lund University Hospital | 2009-09-01 |
| Study of Bortezomib in Combination With Cyclophosphamide and Rituximab (NCT00958256) | M.D. Anderson Cancer Center | 2009-08-01 |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma (NCT00980395) | University of Arizona | 2009-07-07 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma (NCT00891839) | Cephalon | 2009-06-01 |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL (NCT01449344) | Prof. Dr. M. Dreyling (co-chairman) | 2009-05-09 |
| A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT00875667) | Celgene | 2009-04-30 |
| Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study (NCT00877006) | Teva Branded Pharmaceutical Products R&D, Inc. | 2009-04-30 |
| Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (NCT00878254) | University of Miami | 2009-03-25 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815) | M.D. Anderson Cancer Center | 2009-02-17 |
| Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma (NCT00807495) | Millennium Pharmaceuticals, Inc. | 2009-02-10 |
| Lenalidomide and R-CHOP in B-cell Lymphoma (NCT00901615) | Lymphoma Study Association | 2009-01-06 |
| A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial (NCT00737529) | Celgene | 2008-12-22 |
| A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma (NCT00794638) | SymBio Pharmaceuticals | 2008-11-01 |
| Mantel Cell Lymphoma Efficacy of Rituximab Maintenance (NCT00921414) | French Innovative Leukemia Organisation | 2008-09-01 |
| Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas (NCT00783367) | Abramson Cancer Center at Penn Medicine | 2008-07-01 |
| Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (NCT00714259) | University of Alabama at Birmingham | 2008-07-01 |
| Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) (NCT00786851) | Fondazione Italiana Linfomi - ETS | 2008-07-01 |
| Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma (NCT00633594) | SCRI Development Innovations, LLC | 2008-06-01 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT00722137) | Millennium Pharmaceuticals, Inc. | 2008-05-01 |
| Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) (NCT00607854) | University Hospital, Bordeaux | 2008-02-01 |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat (NCT00791011) | Amgen | 2008-02-01 |
| Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (NCT00612183) | SymBio Pharmaceuticals | 2007-12-01 |
| Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab (NCT00609869) | H. Lee Moffitt Cancer Center and Research Institute | 2007-10-01 |
| Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma (NCT00541424) | M.D. Anderson Cancer Center | 2007-09-01 |
| A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. (NCT00472420) | Hoffmann-La Roche | 2007-06-27 |
| Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma (NCT00847223) | Lymphoma Study Association | 2007-06-01 |
| Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (NCT00477412) | M.D. Anderson Cancer Center | 2007-04-03 |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies (NCT00446342) | Sunesis Pharmaceuticals | 2007-02-01 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies (NCT00406809) | AbbVie (prior sponsor, Abbott) | 2006-11-01 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT00407303) | Gemin X | 2006-10-01 |
| Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma (NCT00310037) | Alliance for Clinical Trials in Oncology | 2006-06-01 |
| Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) (NCT00505232) | CABYC | 2006-01-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma (NCT00514475) | Oslo University Hospital | 2005-11-01 |
| Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies (NCT00275431) | Ascenta Therapeutics | 2005-11-01 |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma (NCT00114738) | National Cancer Institute (NCI) | 2005-06-15 |
| Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD (NCT00186628) | Stanford University | 2005-06-01 |
| Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma (NCT01000753) | Children's Oncology Group | 2005-05-30 |
| Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma (NCT00581776) | University of Wisconsin, Madison | 2005-05-01 |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma (NCT00119730) | Dana-Farber Cancer Institute | 2005-02-01 |
| Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma (NCT00201877) | Ohio State University Comprehensive Cancer Center | 2004-12-01 |
| Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (NCT00946374) | Heidelberg University | 2004-07-01 |
| Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00090090) | Spectrum Pharmaceuticals, Inc | 2004-04-01 |
| RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma (NCT00081874) | M.D. Anderson Cancer Center | 2004-04-01 |
| Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma (NCT00088205) | Eli Lilly and Company | 2004-03-01 |
| Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (NCT00075478) | Fred Hutchinson Cancer Center | 2003-10-01 |
| Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab (NCT01456351) | University of Giessen | 2003-09-01 |
| VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (NCT00063713) | Millennium Pharmaceuticals, Inc. | 2003-06-01 |
| Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years (NCT00285389) | French Innovative Leukemia Organisation | 2002-02-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL (NCT01851551) | Acrotech Biopharma Inc. | 2001-09-01 |
| Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia (NCT00022971) | National Cancer Institute (NCI) | 2001-08-15 |
| Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma (NCT00183989) | University of Southern California | 2000-08-01 |
| Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (NCT00005780) | National Cancer Institute (NCI) | 2000-06-01 |
| Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma (NCT00581854) | University of Wisconsin, Madison | 2000-06-01 |
| Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma (NCT00586755) | Duke University | 1998-02-01 |
| Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma (NCT00225212) | Stanford University | 1997-11-01 |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel (NCT05776134) | Kite, A Gilead Company | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma (NCT00022945) | Corixa Corporation | |